ProCE Banner Activity

Navigating Common Challenges When Initiating Guideline-directed Medical Therapy for Patients with HFrEF

Clinical Thought

When foundational therapy for heart failure with reduced ejection fraction (HFrEF) entails 4 drug classes, initiating the regimen can be complex. In this commentary, an expert offers recommendations around 3 common sources of confusion: (1) the urgency of starting therapy, (2) whether and how to sequence therapy, and (3) ideal dosing.

In Collaboration With the Academy of Physician Associates in Cardiology

APAC Logo

Released: June 14, 2022

Expiration: June 13, 2023

Share

Faculty

Javed Butler

Javed Butler, MD, MPH, MBA

Maxwell A. and Gayle H. Clampitt Endowed Chair
President and Chief Research Executive
Baylor Scott and White Research Institute
Dallas, Texas
Senior Vice President, Baylor Scott & White Health
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Acknowledgement

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Target Audience

NPs and PAs

Disclosure

Javed Butler, MD, MPH, MBA: consulting fees: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharmaceuticals, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, Vifor.

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.